search
Back to results

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Primary Purpose

Prostate Cancer

Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
docetaxel
estramustine phosphate sodium
Sponsored by
Herbert Irving Comprehensive Cancer Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Prostate Cancer focused on measuring adenocarcinoma of the prostate, stage IV prostate cancer, recurrent prostate cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: Histologically confirmed metastatic adenocarcinoma of the prostate Failure of androgen ablation (orchiectomy or luteinizing hormone releasing hormone, flutamide) -Rise in PSA greater than 50% of nadir confirmed by 2 measurements 1 week apart -Appearance of new soft tissue lesions -Appearance of new lesions on bone scan Measurable or evaluable disease No symptomatic ascites, pleural effusions, or peripheral edema greater than trace No brain or leptomeningeal involvement PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 No history of coagulopathy Hepatic: Bilirubin no greater than upper limit of normal (ULN) SGOT or SGPT no greater than 2.0 times ULN Alkaline phosphatase no greater than 5.0 times ULN Renal: Creatinine no greater than 2.0 times ULN Cardiovascular: No myocardial infarction within past 6 months Pulmonary: No prior pulmonary embolus Neurologic: No prior cerebrovascular accident No symptomatic peripheral neuropathy greater than grade 1 No significant neurologic or psychiatric disorder (psychotic disorder, dementia, or seizure) Other: No other prior malignancy within past 5 years, except: Excised or curatively irradiated nonmelanomatous skin cancer No other serious illness or medical condition No active infection PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy Endocrine therapy: At least 4 weeks since prior hormonal therapy Radiotherapy: At least 4 weeks since prior radiotherapy At least 6 weeks since prior isotope therapy No prior radiotherapy to greater than 30% of bone marrow Surgery: Not specified Other: At least 4 weeks since prior investigational drugs

Sites / Locations

  • Herbert Irving Comprehensive Cancer Center

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 1, 1999
Last Updated
January 3, 2014
Sponsor
Herbert Irving Comprehensive Cancer Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00002775
Brief Title
Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
Official Title
PHASE I/II STUDY OF DOCETAXEL (TAXOTERE) AND ESTRAMUSTINE COMBINATION CHEMOTHERAPY IN PATIENTS WITH PROSTATE CANCER
Study Type
Interventional

2. Study Status

Record Verification Date
April 2000
Overall Recruitment Status
Unknown status
Study Start Date
February 1998 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Herbert Irving Comprehensive Cancer Center

4. Oversight

5. Study Description

Brief Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel and estramustine in treating patients who have metastatic prostate cancer.
Detailed Description
OBJECTIVES: I. Determine the maximum tolerated dose, toxicity, and pharmacokinetic profile of docetaxel in combination with estramustine in patients with metastatic adenocarcinoma of the prostate. II. Determine the safe dose level of this regimen for Phase II evaluation. III. Determine the efficacy of this regimen with evaluation of objective response rate, duration of response, and time to disease progression in these patients. IV. Determine the duration of survival of these patients on this regimen. V. Evaluate the symptomatic and quality of life effects in these patients. OUTLINE: This is a dose escalation study (phase I). Patients are stratified into one of two risk groups by number of prior chemotherapy regimens (0-2 vs greater than 2) and occurrence and site(s) of prior radiation. Patients receive oral estramustine three times daily beginning 24 hours prior to docetaxel and continuing for 4 days after infusion. Patients receive docetaxel IV over 1 hour every 21 days. Cohorts of 3-6 patients receive escalating doses of docetaxel until the maximum tolerated dose (MTD) is reached (phase I). The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity. A minimum of 6 patients receive treatment at the MTD. Phase II: Patients receive docetaxel IV at the MTD from phase I. Treatment continues in the absence of disease progression or unacceptable toxicity for both phases. Quality of life is assessed. Patients are followed every 3 months until death. PROJECTED ACCRUAL: Approximately 12-37 patients will be accrued for this study within 13-19 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
Keywords
adenocarcinoma of the prostate, stage IV prostate cancer, recurrent prostate cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Enrollment
37 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
docetaxel
Intervention Type
Drug
Intervention Name(s)
estramustine phosphate sodium

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed metastatic adenocarcinoma of the prostate Failure of androgen ablation (orchiectomy or luteinizing hormone releasing hormone, flutamide) -Rise in PSA greater than 50% of nadir confirmed by 2 measurements 1 week apart -Appearance of new soft tissue lesions -Appearance of new lesions on bone scan Measurable or evaluable disease No symptomatic ascites, pleural effusions, or peripheral edema greater than trace No brain or leptomeningeal involvement PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 No history of coagulopathy Hepatic: Bilirubin no greater than upper limit of normal (ULN) SGOT or SGPT no greater than 2.0 times ULN Alkaline phosphatase no greater than 5.0 times ULN Renal: Creatinine no greater than 2.0 times ULN Cardiovascular: No myocardial infarction within past 6 months Pulmonary: No prior pulmonary embolus Neurologic: No prior cerebrovascular accident No symptomatic peripheral neuropathy greater than grade 1 No significant neurologic or psychiatric disorder (psychotic disorder, dementia, or seizure) Other: No other prior malignancy within past 5 years, except: Excised or curatively irradiated nonmelanomatous skin cancer No other serious illness or medical condition No active infection PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy Endocrine therapy: At least 4 weeks since prior hormonal therapy Radiotherapy: At least 4 weeks since prior radiotherapy At least 6 weeks since prior isotope therapy No prior radiotherapy to greater than 30% of bone marrow Surgery: Not specified Other: At least 4 weeks since prior investigational drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Daniel P. Petrylak, MD
Organizational Affiliation
Herbert Irving Comprehensive Cancer Center
Official's Role
Study Chair
Facility Information:
Facility Name
Herbert Irving Comprehensive Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

We'll reach out to this number within 24 hrs